OBJECTIVE: The influence of CD34+ cell dose on the outcome of allogeneic peripheral blood stem cell (PBSC) transplantation after reduced intensity conditioning (RIC) remains controversial. The impact of the number of CD34+ hematoprogenitors infused on transplant outcome and on the incidence of graft versus host disease (GVHD) was analyzed. MATERIALS AND METHODS: Data of 138 patients with advanced hematological diseases who received an allogeneic PBSC transplant after RIC were analyzed. Donors were mobilized with granulocyte colony-stimulating factor and underwent one to three apheresis procedures. Incidence of acute and chronic GVHD and overall and event-free survival (OS and EFS) was determined. RESULTS: The median number of CD34+ cells infused was 5.57 × 10(6) kg(-1) (range: 1.1-15.6). There was no relationship between CD34+ cell dose and neutrophil or platelet engraftment. Patients receiving ≥5 × 10(6) kg(-1) CD34+ cells had a 63.1% 5-year OS when compared with 48.2% for those receiving a lower number (P = 0.024). At 5-year follow-up, there was no significant difference in EFS between the groups (44% vs. 42.8%, P = 0.426). No relationship between CD34+ cell dose and acute GVHD was found (P = 0.1). Relapse rate was the same in patients with and without acute GVHD (P = 0.117). A nonsignificant improvement on OS and EFS in patients who developed chronic GVHD was found (P = 0.57 and 0.41). CONCLUSION: A CD34+ cell dose ≥5 × 10(6) kg(-1) was associated with a significantly higher OS, but no improved EFS in high-risk patients. The number of CD34+ progenitors infused had no influence on the incidence of acute or chronic GVHD.
OBJECTIVE: The influence of CD34+ cell dose on the outcome of allogeneic peripheral blood stem cell (PBSC) transplantation after reduced intensity conditioning (RIC) remains controversial. The impact of the number of CD34+ hematoprogenitors infused on transplant outcome and on the incidence of graft versus host disease (GVHD) was analyzed. MATERIALS AND METHODS: Data of 138 patients with advanced hematological diseases who received an allogeneic PBSC transplant after RIC were analyzed. Donors were mobilized with granulocyte colony-stimulating factor and underwent one to three apheresis procedures. Incidence of acute and chronic GVHD and overall and event-free survival (OS and EFS) was determined. RESULTS: The median number of CD34+ cells infused was 5.57 × 10(6) kg(-1) (range: 1.1-15.6). There was no relationship between CD34+ cell dose and neutrophil or platelet engraftment. Patients receiving ≥5 × 10(6) kg(-1) CD34+ cells had a 63.1% 5-year OS when compared with 48.2% for those receiving a lower number (P = 0.024). At 5-year follow-up, there was no significant difference in EFS between the groups (44% vs. 42.8%, P = 0.426). No relationship between CD34+ cell dose and acute GVHD was found (P = 0.1). Relapse rate was the same in patients with and without acute GVHD (P = 0.117). A nonsignificant improvement on OS and EFS in patients who developed chronic GVHD was found (P = 0.57 and 0.41). CONCLUSION: A CD34+ cell dose ≥5 × 10(6) kg(-1) was associated with a significantly higher OS, but no improved EFS in high-risk patients. The number of CD34+ progenitors infused had no influence on the incidence of acute or chronic GVHD.
Authors: Laura F Newell; Kelsea M Shoop; Rebekah J Knight; Sara N Murray; Rogelyn P Kwock; Carol E Jacoby; Susan Slater; Bryon E Allen; Casondra Ottowa; Brad Cota; Peggy L Appel; Rachel J Cook; Richard T Maziarz; Gabrielle Meyers Journal: Cytotherapy Date: 2019-05-10 Impact factor: 5.414
Authors: Tomasz Czerw; Simona Iacobelli; Vittoria Malpassuti; Linda Koster; Nicolaus Kröger; Marie Robin; Johan Maertens; Patrice Chevallier; Emma Watz; Xavier Poiré; John A Snowden; Jürgen Kuball; Francesca Kinsella; Didier Blaise; Péter Reményi; Jean-Baptiste Mear; Jörg Cammenga; Marie Thérèse Rubio; Sebastien Maury; Etienne Daguindau; Damian Finnegan; Patrick Hayden; Juan Carlos Hernández-Boluda; Donal McLornan; Ibrahim Yakoub-Agha Journal: Bone Marrow Transplant Date: 2021-12-01 Impact factor: 5.483
Authors: Paul S Martin; Shuli Li; Sarah Nikiforow; Edwin P Alyea; Joseph H Antin; Philippe Armand; Corey S Cutler; Vincent T Ho; Natasha Kekre; John Koreth; C John Luckey; Jerome Ritz; Robert J Soiffer Journal: Haematologica Date: 2016-01-14 Impact factor: 9.941
Authors: Patricia van den Hoogen; Saskia C A de Jager; Manon M H Huibers; Arjan H Schoneveld; Yustina M Puspitasari; Gideon B Valstar; Marish I F J Oerlemans; Roel A de Weger; Pieter A Doevendans; Hester M den Ruijter; Jon D Laman; Aryan Vink; Joost P G Sluijter Journal: J Cell Mol Med Date: 2019-09-26 Impact factor: 5.310